Merck & Co Inc has signed deals to sell about 9 million courses of its experimental COVID-19 pill molnupiravir to governments around the world as nations try to tame the pandemic.
The treatment, which received its first regulatory approvals in Britain and Denmark, is not the only one in the game.
In November, U.S. peer Pfizer Inc called an early halt to a trial of its antiviral drug Paxlovid, which according to final analysis showed nearly 90% efficacy in preventing hospitalizations and deaths in high-risk patients.
While a review of both treatments is ongoing in the United States, a panel of expert advisers to the U.S. Food and Drug Administration (FDA) narrowly voted on Dec. 1 to recommend the agency authorize Merck’s antiviral pill.
In the European Union, Merck’s treatment is still under review by the European Medicines Agency (EMA). However, faced with rising COVID-19 cases, the regulator on Nov. 19 issued advice on using the pill for adults ahead of providing any wider recommendation.
EMA last week said that EU member states could use Pfizer’s antiviral drug early after diagnosis of an infection even though its full review for regulatory approval has not been completed yet.
The following tables list countries that have expressed interest in Merck or Pfizer pills, sorted alphabetically:
COUNTRY VOLUME PRICE TIMING OF SOURCE
Australia 300,000 doses
Belgium 10,000 doses
France 50,000 doses
Indonesia 600,000 – 1 December ,
million doses 2021
Italy 50,000 courses
Japan 1.6 mln $1.2
Philippines 300,000 100-150 November
courses pesos 2021
South Korea 200,000
Switzerland 8,640 doses Jan 2022
United 3,100,000 $700 per
States courses course,
COUNTRY VOLUME PRICE TIMING OF SOURCE
Australia 500,000 https://bit.ly/3BTUQeL
Canada 1 mln doses
South Korea 70,000
United 10,000,000 $530 per by the end
States courses course, of 2021
($1 = 85.4800 taka)
(Reporting by Ina Kreutz, Agnieszka Gosciak and Federica Urso; Editing by Jonathan Oatis, Bernadette Baum, Angus MacSwan, Frances Kerry and Paul Simao)
Third COVID-19 outbreak declared this month at Cambridge Memorial Hospital – TheRecord.com
Cambridge Memorial Hospital (CMH) has declared its third COVID-19 outbreak of the month.
The outbreak was announced on Jan. 18 in medicine B (wing B, level 4) with two patients and one staff member testing positive.
A hospital outbreak is declared when two or more patients and/or staff test positive for a respiratory illness that was acquired in hospital within a time frame that is consistent with the epidemiology of the disease, and when there is a link between the cases.
According to CMH, safety precautions added include: enhanced surveillance by increased swabbing and testing non-infected patients and staff; enhanced cleaning, especially to high touch areas; and visits to inpatients have been paused for the entire hospital as of Jan. 8.
Virtual visits and phone connections for patients and families can be arranged.
The outbreak in medicine B could be declared over on Jan. 28 after 10 consecutive days with no new infections.
The hospital is still in outbreak in two other units, rebab and inpatient surgery.
The rehabilitation unit outbreak was declared Jan. 4.
As of Jan. 19, 12 patients and three staff have been infected, with the last positive test detected on Jan. 16, targeting the earliest possible end date at Jan. 26 if there are no new cases.
The inpatient surgery outbreak was declared Jan. 7 and at this time, seven patients and six staff have been infected. The last positive test was detected on Jan. 15, which targets the outbreak’s end date at Jan. 25 should there be no new cases.
Those who had COVID-19 and are vaccinated have best protection, study finds – National | Globalnews.ca – Globalnews.ca
A new study in two states that compares coronavirus protection from prior infection and vaccination concludes getting the shots is still the safest way to prevent COVID-19.
The study examined infections in New York and California last summer and fall and found people who were both vaccinated and had survived a prior bout of COVID-19 had the most protection.
But unvaccinated people with a past infection were a close second. By fall, when the more contagious delta variant had taken over but boosters weren’t yet widespread, that group had a lower case rate than vaccinated people who had no past infection.
The Centers for Disease Control and Prevention, which released the study Wednesday, noted several caveats to the research. And some outside experts were cautious of the findings and wary of how they might be interpreted.
“The bottom line message is that from symptomatic COVID infection you do generate some immunity,” said immunologist E. John Wherry of the University of Pennsylvania. “But it’s still much safer to get your immunity from vaccination than from infection.”
Vaccination has long been urged even after a prior case of COVID-19 because both kinds of protection eventually wane — and there are too many unknowns to rely only on a past infection, especially a long-ago one, added immunologist Ali Ellebedy at Washington University in St. Louis.
“There are so many variables you cannot control that you just cannot use it as a way to say, `Oh, I’m infected then I am protected,”’ Ellebedy said.
Quebec’s COVID-19 death toll highest in the country
The research does fall in line with a small cluster of studies that found unvaccinated people with a previous infection had lower risks of COVID-19 diagnosis or illness than vaccinated people who were never before infected.
The new study’s findings do make sense, said Christine Petersen, a University of Iowa epidemiologist. She said a vaccine developed against an earlier form of the coronavirus is likely to become less and less effective against newer, mutated versions.
However, experts said, there are a number of possible other factors at play, including whether the vaccine’s effectiveness simply faded over time in many people and to what extent mask wearing and other behaviors played a part in what happened.
Another thing to consider: The “staunchly unvaccinated” aren’t likely to get tested and the study only included lab-confirmed cases, Wherry said.
“It may be that we’re not picking up as many reinfections in the unvaccinated group,” he said.
CDC officials noted other limitations. The study was done before the omicron variant took over and before many Americans received booster doses, which have been shown to dramatically amplify protection by raising levels of virus-fighting antibodies. The analysis also did not include information on the severity of past infections, or address the risk of severe illness or death from COVID-19.
The study authors concluded vaccination “remains the safest strategy” to prevent infections and “all eligible persons should be up to date with COVID-19 vaccination.”
The researchers looked at infections in California and New York, which together account for about 18 per cent of the U.S. population. They also looked at COVID-19 hospitalizations in California.
Overall, about 70 per cent of the adults in each state were vaccinated; another five per cent were vaccinated and had a previous infection. A little under 20 per cent weren’t vaccinated; and roughly five per cent were unvaccinated but had a past infection.
Toronto to collect COVID-19 data through wastewater
The researchers looked at COVID-19 cases from the end of last May until mid-November, and calculated how often new infections happened in each group. As time went on, vaccine-only protection looked less and less impressive.
By early October, compared with unvaccinated people who didn’t have a prior infection, case rates were:
— Six-fold lower in California and 4.5-fold lower in New York in those who were vaccinated but not previously infected.
— 29-fold lower in California and 15-fold lower in New York in those who had been infected but never vaccinated.
— 32.5-fold lower in California and 20-fold lower in New York in those who had been infected and vaccinated.
But the difference in the rates between those last two groups was not statistically significant, the researchers found.
Hospitalization data, only from California, followed a similar pattern.
© 2022 The Canadian Press
Over 1.2 million people died from drug-resistant infections in 2019 – study
More than 1.2 million people died in 2019 from infections caused by bacteria resistant to multiple antibiotics, higher than HIV/AIDS or malaria, according to a new report published on Thursday.
Global health officials have repeatedly warned about the rise of drug-resistant bacteria and other microbes due to the misuse and overuse of antibiotics, which encourages microorganisms to evolve into “superbugs”.
The new Global Research on Antimicrobial Resistance report, published in The Lancet, revealed that antimicrobial resistance (AMR) was directly responsible for an estimated 1.27 million deaths and associated with about 4.95 million deaths. The study analysed data from 204 countries and territories.
“These new data reveal the true scale of antimicrobial resistance worldwide… Previous estimates had predicted 10 million annual deaths from AMR by 2050, but we now know for certain that we are already far closer to that figure than we thought,” said Chris Murray, co-author of the study and a professor at the University of Washington.
Last year, the World Health Organization warned that none of the 43 antibiotics in development or recently approved medicines were enough to combat antimicrobial resistance.
Cornelius Clancy, professor of Medicine at the University of Pittsburgh, said one of the ways to tackle AMR is to look at a new treatment model.
“The traditional antibiotic model that we’ve had for past number of decades since penicillin. I think it is tapped out.”
Most of 2019’s deaths were caused by drug resistance in lower respiratory infections such as pneumonia, followed by bloodstream infections and intra-abdominal infections.
AMR’s impact is now most severe in Sub-Saharan Africa and South Asia, while around one in five deaths is in children aged under five years.
There was limited availability of data for some regions, particularly many low and middle-income countries, which may restrict the accuracy of the study’s estimates.
Clancy said the focus has been on COVID-19 for the past two years, but AMR is a “long-term kind of challenge”.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Krishna Chandra Eluri and Devika Syamnath)
Airlines say Canadian flights unaffected by turmoil over 5G wireless launch in U.S. – CP24 Toronto's Breaking News
Scientists study travels of meteorite that landed in B.C. in October – Vancouver Sun
Change your Perspective (Plastic use)
Silver investment demand jumped 12% in 2019
Europe kicks off vaccination programs | All media content | DW | 27.12.2020 – Deutsche Welle
Iran anticipates renewed protests amid social media shutdown
Sports10 hours ago
Soccer-USMNT embrace the cold as World Cup qualifying heats up
Art22 hours ago
At Art Basel, FLUF Haus Breaks Barrier Between Metaverse And Physical World – Forbes
News11 hours ago
Trudeau says Canada fears armed conflict in Ukraine as Russia ramps up aggression – CTV News
Art19 hours ago
300-pound local art heist took 4 minutes | News | pentictonherald.ca – pentictonherald.ca
Art22 hours ago
First artist chosen for Art @ the Library – Delta-Optimist
Economy21 hours ago
Crypto VC Firm Inflection Launches $40M Fund to Build ‘Open Economy’ – CoinDesk
Health16 hours ago
HPHA declares COVID-19 outbreak over at local hospital – BlackburnNews.com
Politics19 hours ago
Opinion: Canadians will pay the price for the Liberals playing politics with trucking – Calgary Herald